FDA authorizes AstraZeneca COVID prevention drug for immunocompromised people

According to the FDA, it may be effective for six months.

(Eli Lilly’s treatmentwas authorized last week for children under 12 who are at high risk.)

AstraZeneca said its treatmentreduced riskof hospitalization and death by 83%.

COVID-19 treatment pills made byMerckandPfizerare expected to be available soon to high-risk adults.